A Phase III Study of Bumetanide Oral Liquid Formulation for the Treatment of Children and Adolescents Aged Between 7 and 17 Years with Autism Spectrum Disorder (SIGN 1 Trial): Participant Baseline Characteristics-Reference-Cited by-同舟云学术

A Phase III Study of Bumetanide Oral Liquid Formulation for the Treatment of Children and Adolescents Aged Between 7 and 17 Years with Autism Spectrum Disorder (SIGN 1 Trial): Participant Baseline Characteristics

Published:2022-03-16 Issue: Volume: Page:
ISSN:0009-398X
Container-title:Child Psychiatry & Human Development
language:en
Short-container-title:Child Psychiatry Hum Dev

Author:

Georgoula Christina,Ferrin Maite,Pietraszczyk-Kedziora Bozena,Hervas Amaia,Marret Stéphane,Oliveira Guiomar,Rosier Antoine,Crutel Véronique,Besse Emmanuelle,Severo Cristina Albarrán,Ravel Denis,Fuentes Joaquin

Funder

servier

Publisher

Springer Science and Business Media LLC

Subject

Psychiatry and Mental health,Developmental and Educational Psychology,Pediatrics, Perinatology and Child Health

Link

https://link.springer.com/content/pdf/10.1007/s10578-022-01328-5.pdf

Reference68 articles.

1. American Psychiatric Association (2013) Diagnostic and statistical manual of mental disorders (DSM-5®) (American Psychiatric Pub)

2. Chiarotti F, Venerosi A (2020) Epidemiology of autism spectrum disorders: a review of worldwide prevalence estimates since 2014. Brain Sci 10:274

3. Elsabbagh M, Divan G, Koh YJ, Kim YS, Kauchali S, Marcín C et al (2012) Global prevalence of autism and other pervasive developmental disorders. Autism Res 5:160–179